Q4 FY2025 · ended Dec 31, 2025 · Revenue $59,000, -69.3% YoY · Filed Mar 23, 2026
Avalo Therapeutics, Inc. (AVTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Sep 30, 2026 it held $462.8 million in cash and investments and $153,000 in total debt.
Revenue
$59,000
-69.3% vs year-ago quarter
Net income
$-18.95M
+38.1% vs year-ago quarter
Operating cash flow
$-11.54M
+29.5% vs year-ago quarter
Free cash flow
—
EPS
$-0.34
+84.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
57.82M
+218.9% vs year-ago quarter
Net cash
$462.62M
Q3 FY2026
Operating margin
-33461.0%
Q4 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AVTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wayne, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534120
- Former names
- Cerecor Inc. (until Aug 18, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $59,000 | $0 |
| Operating income | -$23.4M | -$31.5M | -$20.9M | -$19.7M | -$19.2M |
| Net income | -$18.9M | -$36.4M | -$19.6M | -$13.7M | -$30.6M |
| Diluted EPS | -$0.34 | -$0.83 | -$0.98 | — | -$2.19 |
| Operating cash flow | -$11.5M | -$20.0M | -$17.7M | -$14.2M | -$16.4M |
| Total assets | $481.4M | $490.8M | $99.9M | $116.5M | $125.1M |
| Total liabilities | $44.9M | $42.1M | $31.6M | $33.4M | $33.6M |
| Stockholders' equity | $436.5M | $448.7M | $68.3M | $83.0M | $91.5M |
| Cash and investments | $462.8M | $472.2M | $82.0M | $98.3M | $111.6M |
| Total debt | $153,000 | $242,000 | $328,000 | $427,000 | $555,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Agreement ended
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 23, 2026 | Jun 23, 2026 |
All 1006 Avalo Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.